Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Procter & Gamble

Warren Buffett's investing company, Berkshire Hathaway, let go of two stocks that have more than 60 years of consecutive annual dividend raises under their belts. Berkshire Hathaway closed its Johnson & Johnson position, possibly in response to the healthcare conglomerate's recent spinoff.

Warren Buffett Dumped These 2 Top Dividend Stocks. Should You Follow His Lead?

Biogen

Pfizer

The United States leads globally in the healthcare sector, with its innovative healthcare stocks drawing attention from an impressive $4.3 trillion in spending. As the American Medical Association highlights, this expenditure equals nearly $13,000 per person, contributing 18.3% to the nation's GDP.

Healthcare Heroes: 3 Stocks Innovating in Medicine and Wellness

Chevron

Walgreens

Walgreens, Chevron, and Johnson & Johnson are the three worst performers on the Dow Jones Industrial Average in 2023. All three have clear reasons for their underperformance.

Is It Time to Buy the Dow Jones' 3 Worst Performing Stocks This Year?

Amgen

Cisco Systems

Dow Inc

Coca-Cola

Verizon

It's time for followers of the Dogs of the Dow stock-picking strategy to rebalance their portfolios.

What Are the Dogs of the Dow for 2024?

Bristol-Myers

Estee Lauder

Moderna

NextEra Energy

Exxon Mobil

Investors scored big-time on the biggest S&P 500 stocks this year. But those who picked the wrong stocks suffered mightily.

Investors Lose $426 Billion On These 8 Giant Losers This Year

Realty Income Corp

Waste Management

While the upcoming new year generally brings optimistic sentiment to the market, investors should be prepared for anything, which is why solid dividend stocks represent an incredibly relevant topic. Much like playing the hot corner, you've got to be ready for anything.

7 Rock-Solid Dividend Stocks to Trust in Difficult Times

Sponsored: Tips for Investing A financial advisor can help you understand the advantages and disadvantages of investment properties.

6 Reasons to Avoid Johnson & Johnson (JNJ) At All Costs

Apple

Abbott Labs

Vertex Pharmaceuticals

Your year-end bonus looks great now. But it may look even better in a few years if you invest it in some top-quality stocks.

5 Top Stocks to Buy With Your End-of-the-Year Bonus

Johnson & Johnson is entering the surgical robotics market with the Ottava surgical system, potentially gaining a strong market position. Ottava's design offers competitive advantages over the dominant da Vinci system, including a smaller footprint and potential cost savings for healthcare organizations. The global surgical robotics market is expected to grow rapidly providing a significant growth opportunity for JNJ, which is well-positioned with its established capabilities and brand reputation.

Johnson & Johnson: Ottava Surgical Robot Is A Growth Tailwind

McDonald's

PepsiCo

You heard it here: 2024 could be an excellent year for stocks. The economy is improving, and specifically the third-quarter results were better than expected.

Build Your Future Portfolio: 3 Generous Dividend Stocks

First Solar

Kraft Heinz

Lockheed Martin

Sempra Energy

Vulcan Materials

Soon, it will be that favorite time of the quadrennial cycle where American citizens will decide the future of this great nation, subsequently necessitating a discussion about election year stocks. On surface level, you might think that such periods would be rather disastrous for equities, especially with the vituperative environment.

7 Stocks That Might Win on Election Year Uncertainty

Mastercard

York Water

The Dow Jones Industrial Average, S&P 500, and Nasdaq Composite have traded off bear and bull markets in each of the past four years. Time-tested "safe stocks" offer a smart place for investors to put their money to work in the new year.

Got $1,000? 5 of the Safest Stocks to Buy for 2024

CRISPR Therapeutics

Teladoc

You probably won't get rich with just one stock, but you could reach your goal by investing in a portfolio of solid companies over time. Two of these players offer you revenue growth potential, and the third could lift your investment thanks to dividends.

3 Healthcare Stocks That Could Help Make You a Millionaire

In the latest trading session, Johnson & Johnson (JNJ) closed at $155.44, marking a +0.18% move from the previous day.

Johnson & Johnson (JNJ) Increases Yet Falls Behind Market: What Investors Need to Know

AbbVie

In the realm of investment, pharma dividend stocks are a beacon for both stability and growth. This sector not only enhances the quality of life on a global scale but also presents lucrative opportunities for long-term investors.

3 of the Most Attractive Dividend Stocks in the Pharma Space

Don't look now. But dividends are back in vogue.

The Dogs of the Dow May Pay Big Dividends in 2024

Enterprise Products Partners

AT&T

2023 has been mixed for growth stocks but I believe the worst is over. There is high optimism in the stock market as we end the year on a high note.

The 7 Most Undervalued Dividend Stocks to Buy in December

The Dow Jones Industrial Average, or Dow 30, is an index of 30 blue-chip stocks that, taken together, is supposed to serve as a bellwether for the American economy. But that doesn't mean that every stock in the Dow is a strong performer.

3 Dow Stocks I Wouldn't Touch With a 10-Foot Pole

MONTGOMERY, Ala.--(BUSINESS WIRE)--Attorneys representing ovarian cancer victims who are suing Johnson & Johnson (NYSE: JNJ) warn that J&J's declared bankruptcy strategy to end talc litigation will not succeed as some of the nation's most accomplished trial lawyers gear up for a series of jury trials in 2024. Attorneys Andy Birchfield, Jason Itkin and Mike Papantonio, who represent thousands of ovarian cancer plaintiffs, say recent limited settlements touted by the company confirm that.

Key Talc Lawyers: Planned “Prepack” J&J Bankruptcy is “Farce” and Improper Litigation Tactic

Duke Energy

Lowe's

Microsoft

Although investors have some evidence of a possible economic recovery, they should still consider defensive stock picks. We just don't know what will happen next.

Economic Safety Nets: 7 Defensive Stocks Providing Portfolio Stability

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, January 23rd to review fourth-quarter results. Joaquin Duato, Chairman and CEO, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and prese.

News for Johnson & Johnson Stock (JNJ)